RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Clinical trials for RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on Hard-to-Treat brain cancer
Disease control Recruiting nowThis early-phase study tests a personalized therapy where a patient's own immune cells are modified to recognize and attack lymphoma cells in the brain. It is for people aged 18-75 with central nervous system lymphoma that has relapsed or not responded to prior treatments. The go…
Matched conditions: RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1 • Sponsor: Beijing Boren Hospital • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
New hope for brain lymphoma: tirabrutinib takes on standard combo in phase 3 trial
Disease control Recruiting nowThis study compares the experimental drug tirabrutinib alone with a standard combination of rituximab and temozolomide in people whose primary central nervous system lymphoma has come back or not responded to prior treatment. About 132 participants will be randomly assigned to on…
Matched conditions: RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE3 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 06, 2026 16:03 UTC